36
total announcements
LALPATHLAB.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹30,829 Cr
P/E (TTM)
56.9
P/E (Forward)
42.0
EPS (TTM)
₹32.40
52W Low
₹1,272.60
52W High
₹2,038.60
Dividend Yield
1.08%
Beta
0.16
Price / Book
12.3
Debt / Equity
7.8
Revenue (TTM)
₹2,891 Cr
Gross Margin
60.20%
Operating Margin
25.46%
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its un-audited financial results for the quarter ended June 30, 2026, with revenue increasing by 19.1% to Rs 798 Cr, EBITDA increasing by 28.7% to Rs 247 Cr, and PAT increasing by 27.2% to Rs 170 Cr. The company has also declared an interim dividend of 50% and has made two acquisitions.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Grant of 119300 Stock Options, approved un-audited (Standalone & Consolidated) Financial Results for the Quarter ended June 30, 2026, declaration of Interim Dividend of INR 5/- per equity share, and acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its unaudited financial results for the quarter ended June 30, 2026, and has also approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited through its subsidiaries.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its record date for the purpose of dividend payment as July 30, 2026, and declared an interim dividend of INR 5 per equity share.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its un-audited financial results for the quarter ended June 30, 2026, and approved an interim dividend of INR 5 per equity share. The company also approved the granting of stock options to eligible employees and noted the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has declared an interim dividend of Rs. 5 per equity share, with a record date of July 30, 2026, and the dividend will be paid within 30 days of its declaration.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its financial results for the quarter ended June 30, 2026, and approved an interim dividend of INR 5 per equity share. The company also approved the granting of stock options to eligible employees and noted the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has received an appellate order from the Income Tax Department, allowing their appeal and deciding in their favor, with the deduction on ESOP expenses of INR 32,66,18,927 being allowed.
Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Ltd. has informed the Exchange about Schedule of meet for Q1 FY27 earnings conference call on July 24, 2026.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance under Regulation 74(5) for the quarter ended June 30, 2026.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about the dispatch of Notice of 32nd Annual General Meeting and Annual Report for FY 2025-26 to the Members of the Company.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has dispatched a letter to its members providing a web-link to access the Annual Report for FY 2025-26, as per Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has submitted its Business Responsibility and Sustainability Report for the Financial Year 2025-26, as required by SEBI regulations.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Notice of Annual General Meeting to be held on July 25, 2026.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about a copy of newspaper publication regarding the 32nd Annual General Meeting of the Company to be held on July 25, 2026 through Video Conferencing/Other Audio Visual Means.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the Board meeting to consider un-audited financial results for the quarter ending June 30, 2026.